Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
February 28, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
-- FDA Advisory Committee Votes 8 to 5 Recommending FDA Wait for the Results from the OngoingPhase 3 BOSTON Study to Make an Approval Decision for Selinexor -- -- Company Working with FDA to Evaluate...
Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma
February 26, 2019 17:47 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)...
Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
February 26, 2019 12:31 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that NASDAQ has halting trading of the Company’s...
Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer
February 25, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
-- Formerly of Alnylam Pharmaceuticals, Praecis Pharmaceuticals, and KPMG; Brings Over 18 Years of Financial Leadership Experience Within the Life Sciences Industry -- NEWTON, Mass., Feb. 25, 2019 ...
Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
February 21, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year...
Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
February 07, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Oncologic Drugs Advisory Committee...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma
January 08, 2019 12:20 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has submitted a Marketing Authorization...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 02, 2019 16:05 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...